@FiercePharma: ICYMI from FiercePharmaAsia: Ranbaxy merger showing sharp cons as well as pros for Sun Pharma. Item | Follow @FiercePharma
@EricPFierce: ICYMI from FiercePharmaManufacturing: Japan's Chugai says its mAb work with Roche means a need for a $309M API plant expansion. Article | Follow @EricPFierce
@CarlyHFierce: SOMEbody got burned out on grammar by slide 82 of the $VRX presentation. "Why does R&O and Philidor have the same phone number?" | Follow @CarlyHFierce
> Merck & Co. ($MRK) touted top-line data showing that its immuno-oncology drug Keytruda helped certain patients with non-small-cell lung cancer live longer. Release
> Endo ($ENDP) and BioDelivery Sciences won FDA approval for a dissolvable pain treatment, Belbuca, but a side-effects warning could inhibit uptake. Report
> GlaxoSmithKline ($GSK) won European backing to expand approval of Volibris, a treatment for pulmonary arterial hypertension, to use in combination with other meds. Report
> Novartis' ($NVS) psoriasis med Cosentyx got a thumbs up from Europe's drug approval committee for new uses in ankylosing spondylitis and psoriatic arthritis. Report
> Rare disease specialist Alexion Pharmaceuticals ($ALXN) nabbed an FDA clearance for Strensiq, which treats hypophosphatasia, a genetic disorder. Release | Report
Medical Device News
@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev
@EmilyWFierce: ICYMI Friday: Kadcyla's miss in stomach cancer dents Roche's effort to reap more from new drugs. FiercePharma story | Follow @EmilyWFierce
> Healthcare, wellness drive Philips growth as it works to shed lighting, maintain cautious M&A strategy. Story
> Report: Buyer interest heating up for Swiss Dx company Unilabs. More
> Walgreens freezes partnership with Theranos amid testing fallout. Report
Biotech News
@FierceBiotech: ICYMI: AstraZeneca's gout drug wins faint praise from FDA advisers. Article | Follow @FierceBiotech
@JohnCFierce: ICYMI: Alexion wins priority review voucher with FDA OK of Strensiq. Report | Follow @JohnCFierce
@DamianFierce: This is an excellently reported $VRX/Philidor story that deserves a more alluring headline. Perhaps "One Weird Trick To Boost Drug Revenue," and then they could do like a quiz to "Find Your Philidor Alter-Ego" WSJ story | Follow @DamianFierce
> Endo and BDSI pick up FDA approval for a cheek-delivered pain drug. Story
> Vertex pays $105M to kick off gene editing pact with CRISPR Therapeutics. Article
> Key investor pushes for GSK breakup after pipeline fails to deliver. Report
Animal Health News
> Subway ups the ante on antibiotic-free meat pledge. More
> Lilly charts strong Q3 results bolstered by Novartis Animal Health addition. Item
> After downsizing and delaying IPO, Oasmia pulls off Nasdaq debut. Story
> New app offers remote veterinary visits for pet owners. Article
> Parnell shares advance on strong Q3 revenue growth. Report
Biotech IT News
> Big Pharma follows cash-strapped seniors onto the darknet. Story
> Silicon Valley's thrust into biotech sparks scramble for data scientists. Report
> J&J inks deal to access Nuevolution's informatics-enabled discovery platform. News
> Genentech deal continues big 2015 for in silico specialist Nimbus. Article
> Novartis, Qualcomm joint venture backs $6.5M Series A round for Science 37. More
Pharma Marketing News
> AbbVie faces the music with Express Scripts over FDA's Viekira Pak warning. Item
> J&J's Yondelis finally captures FDA nod, but path to big sales could be steep. More
> The eyes may have it, but pharma still needs convincing on branded visual comms. Report
> Sales reps need to bone up on tech skills as drug launches move digital. Story
> Biogen to put layoffs savings toward DTC, patient support for lagging Tecfidera. Article
And Finally... The British publisher Pearson tapped former Eli Lilly & Co. ($LLY) CEO Sidney Taurel as its new non-executive chairman. Report